Skip to main content
. 2020 Nov 18;3(11):e2025127. doi: 10.1001/jamanetworkopen.2020.25127

Figure 2. Proportion of Medicare Beneficiaries of Black, White, and Other Races/Ethnicities Initiating Combination Therapy With an Angiotensin-Converting-Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB), β-Blocker, Thiazide-Type Diuretic, or Calcium Channel Blocker, by Calendar Year.

Figure 2.